AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 171 min read$ROIV

Epperly Melissa B, sold $196K of ROIV

Epperly Melissa B, sold 4,938 shares of Roivant Sciences Ltd. (ROIV) at an average of $39.74 ($39.65–$40.38, $0.20M total) across 2 trades on 2026-09-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Epperly Melissa B,
Published Sep 17, 2026, 10:43 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 10:48 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ROIV
Bearish
medium confidence
Mentioned
$ROIV
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ROIVBearishLow
01

Why it matters

The disclosed sale provides a data point for monitoring insider sentiment but is unlikely to drive price movement.

02

Market read

Routine insider sale with modest size; limited trading relevance.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed.

Relevance 3/10Novelty 5/10Timing: filed after market on 2026-09-17

Background

SEC Form 4 filing discloses insider transactions for public companies.

Company-level read

Ticker impact

$ROIVBearishMedium confidence
Context

Director Melissa Epperly sold 4,938 shares (~$196K) via a 10b5-1 plan on 2026-09-15.

Expected impact

Minimal short-term price dip, likely within normal volatility range.

Evidence & confidence

The transaction represents less than 0.2% of outstanding shares and is pre‑arranged, limiting informational value.

Market effects

Sector

No material impact on the biotech sector; insider activity is routine.

Regional

Limited to US investors tracking Roivant; negligible broader market effect.

Global

None

Counterpoint

What could challenge this read

The sale could be purely portfolio rebalancing; not a bearish signal.

Key entities

  • Company
    Roivant Sciences Ltd.

    Biopharma company listed on Nasdaq under ticker ROIV.

  • Individual
    Melissa B. Epperly

    Director of Roivant Sciences Ltd.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ROIV insider trading history →

Related articles

OCT 5
$ROIVMedAI 8/10

Transcript: Roivant Sciences Q1 2027 Earnings Conference Call - Roivant Sciences (NASDAQ:ROIV)

Roivant Sciences (ROIV) reported Q1 2026 results, highlighting a quiet quarter with progress in its pipeline, particularly brepocitinib's Phase 3 study. The company received a $950M settlement from Moderna and has ongoing litigation against Pfizer and BioNTech. Financially, ROIV reported $200M in R&D expenses, $100M in non-GAAP G&A expenses, and a cash position of nearly $4B. Management expects a busy second half with brepocitinib's launch and other pipeline updates.

benzinga.com3 min
OCT 5
Med

Roivant, the ‘inveterate drug hunters’, enters commercial era with Lisraya

Roivant Sciences, a biopharma company with a unique hub-and-spoke model, is transitioning into a commercial phase with the launch of Lisraya, an oral TYK2/JAK inhibitor for dermatomyositis. CEO Matt Gline aims to differentiate the company with a commercial portfolio, including Lisraya, Pulmovant’s mosliciguat, and Immunovant’s IMVT-1402. Leerink Partners estimates Lisraya could generate $7.9 billion in sales by 2035, with mosliciguat's expectations raised to $9.8 billion.

biospace.com3 min
SEP 24
$ROIVMedAI 8/10

Roivant’s Lung Drug Clears Phase 2 Test: Is Another Major Pipeline Asset Emerging?

Roivant Sciences (ROIV) shares rose 17% after reporting positive Phase 2 results for mosliciguat, its experimental treatment for pulmonary hypertension. The drug met primary and secondary endpoints, reducing pulmonary vascular resistance by 56.3% and improving six-minute walk distance. J.P. Morgan estimates peak sales of $1.5B, though this is an analyst forecast. Roivant is now advancing to Phase 3 trials.

insidermonkey.com3 min